How CIMZIA Works For You

CIMZIA:
The First And Only FDA-Approved Therapy

For adults with non-radiographic axial spondyloarthritis

While pain relievers may provide temporary relief for symptoms of non-radiographic axial spondyloarthritis (nr-axSpA), they do not address the underlying cause of the disease, which is inflammation. CIMZIA is the first and only treatment proven to improve symptoms and disease activity over time. See how CIMZIA could work for you.

CIMZIA® | Disease Activity. See full information on this page.
Improved Disease Activity

In a clinical trial, nearly 5 out of 10 people taking CIMZIA had major improvement in disease activity within 52 weeks—for some in as fast as 2 weeks.*

*47% of CIMZIA patients at 52 weeks vs. 7% of placebo patients; 21% of CIMZIA patients at 2 weeks vs. 1% of placebo patients.

CIMZIA® | Spinal Pain. See full information on this page.
Less Spinal Pain

People on CIMZIA experienced 33% less back pain than placebo-treated patients at week 12.

In a clinical trial, patients on CIMZIA experienced these results. Results shown above are based on a dose of 200 mg every two weeks. Results may vary; every person taking CIMZIA is different and responds differently to therapy.

Join our mailing list and get ongoing support for your nr-axSpA symptoms.

The Logic of a Biologic Like CIMZIA

CIMZIA is a biologic, meaning it is a drug derived from living sources that copy the effects of substances naturally made by your body’s immune system. As an anti-tumor necrosis factor (TNF) biologic, CIMZIA works to block the extra TNF that leads to inflammatory pain. Learn more about TNF and why an anti-TNF may be the most appropriate treatment for nr-axSpA symptoms.

CIMZIA's doctor discussion guide is available for download to assist with your next conversation with your rheumatologist

How Disruptive Is Your Inflammatory Back Pain?

Let's take a look at how you're managing your symptoms. If your back pain has lasted 3 months or longer and worsens with rest, you may have inflammation caused by non-radiographic axial spondyloarthritis.